- Home
- TERN vs PVLA Comparison
TERN vs PVLA Comparison
Compare TERN & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- PVLA
- Stock Information
- Founded
- TERN 2017
- PVLA 2015
- Country
- TERN United States
- PVLA United States
- Employees
- TERN N/A
- PVLA N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- PVLA Health Care
- Exchange
- TERN Nasdaq
- PVLA Nasdaq
- Market Cap
- TERN 263.8M
- PVLA 253.2M
- IPO Year
- TERN 2021
- PVLA N/A
- Fundamental
- Price
- TERN $3.11
- PVLA $24.13
- Analyst Decision
- TERN Buy
- PVLA Strong Buy
- Analyst Count
- TERN 5
- PVLA 7
- Target Price
- TERN $15.63
- PVLA $46.29
- AVG Volume (30 Days)
- TERN 738.7K
- PVLA 52.4K
- Earning Date
- TERN 05-08-2025
- PVLA 05-15-2025
- Dividend Yield
- TERN N/A
- PVLA N/A
- EPS Growth
- TERN N/A
- PVLA N/A
- EPS
- TERN N/A
- PVLA N/A
- Revenue
- TERN N/A
- PVLA N/A
- Revenue This Year
- TERN N/A
- PVLA N/A
- Revenue Next Year
- TERN N/A
- PVLA N/A
- P/E Ratio
- TERN N/A
- PVLA N/A
- Revenue Growth
- TERN N/A
- PVLA N/A
- 52 Week Low
- TERN $1.87
- PVLA $11.17
- 52 Week High
- TERN $11.40
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- TERN 54.76
- PVLA N/A
- Support Level
- TERN $2.84
- PVLA N/A
- Resistance Level
- TERN $3.17
- PVLA N/A
- Average True Range (ATR)
- TERN 0.19
- PVLA 0.00
- MACD
- TERN 0.01
- PVLA 0.00
- Stochastic Oscillator
- TERN 73.98
- PVLA 0.00
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.